FABRICATION AND IN-VITRO EVALUATION OF CEFIXIME NANOPARTICLES USING GUM KONDAGOGU AND CHITOSAN AS MATRIX FORMERS

Cefixime is more effective in treating multi drug resistant typhoid fever but the major limitation was its poor bioavailability with short half- life. The present investigation was attempted to develop a natural polymer based nanoparticles containing cefixime using gum kondagogu and chitosan as polymers for customising the drug release profile to achieve an effective therapeutic concentration by increasing its solubility and bioavailability. The cefixime nanoparticles were prepared by the modified coacervation method and evaluated for particle size, zeta potential, morphological studies (SEM, TEM and AFM), entrapment efficiency, in-vitro drug release studies and in-vitro antimicrobial efficiency studies. The prepared drug nanoparticles found to be average mean particle size in range from 80.6±3.5 to 230.6±7.3nm and entrapment efficiency was found to be 78.0±1.5 to 93.2±2.5%. The in-vitro drug release showed a biphasic pattern with initial burst release followed by sustained drug release up to 32h. The MIC50 of prepared formulation was one fold lesser than pure cefixime for Salmonella Typhi isolates. The disc agar diffusion (DAD) test confers that the zone of inhibition was found to be better for the formulation against pure cefixime. In conclusion, the developed Cefixime nanoparticles support to customise the drug release profile and better zone of inhibition with minimum concentration which provoke better patient compliance